A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Recurrent Glioblastoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Immorna Biotherapeutics, Inc.
Start Date
February 4, 2023
End Date
February 28, 2026
Administered By
Duke Cancer Institute
Awarded By
Immorna Biotherapeutics, Inc.
Start Date
February 4, 2023
End Date
February 28, 2026